What does the future hold for antibody-drug conjugate therapies in ovarian cancer?

Expert Opinion on Biological Therapy 2026 Open access

Read full text
Authors: Page C. Widick, Ursula A. Matulonis, Meghan Shea
DOI: 10.1080/14712598.2026.2645102
Cited by: 0
References: 14

Abstract

1. In 2022, there were nearly 325,000 new diagnoses of ovarian cancer globally with over 200,000 ovarian cancer-related deaths [1]. Amongst the 80% of women with advanced-stage disease at diagnosis...

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment Monoclonal and Polyclonal Antibodies Research PARP inhibition in cancer therapy

Publication details

Journal / source
Expert Opinion on Biological Therapy
Volume
26
Issue
3
Pages
219–224
Publication date
4 March 2026
Language
EN